Investigating new approaches to PTSD
Neuritek Therapeutics is developing an investigational, mechanism-based approach to post-traumatic stress disorder, informed by research into the biological pathways involved in trauma and stress.
Our development strategy builds on prior human research and emphasizes careful clinical evaluation. Published Phase 1 research on V158866 evaluated safety, tolerability, and pharmacology in healthy volunteers. Effectiveness in people with PTSD remains to be established.
Our goal is to translate scientific understanding into potential treatments that can make a meaningful difference for patients and families.
Neuritek’s therapeutic model: innovative, efficient, and
solution-oriented.
State of the art facilities. Clinical and research labs.
Established academic and industry collaborations. We bring academic and industry knowledge to our patients.
Rich drug pipeline. Immediate drug candidates based upon their proven relevance to PTSD.
10 years of proprietary PTSD research. A new approach to drug development process.
Although several psychotherapies are available to treat PTSD, novel pharmacotherapy development has lagged and only recently have intensive basic science and clinical studies yielded novel, potentially breakthrough discoveries that have the potential to introduce a new era for trauma survivors with PTSD.
Neuritek’s clinical development program is based on a substantial body of scientific data that have directly implicated the body’s G-protein coupled receptors in the development of PTSD.
We focus our research and development efforts on activating the body’s GPCRs system–a complex network of receptors, molecules, and enzymes that work together to help maintain cellular balance, or homeostasis, within our bodies. This balance allows cells, organs, and systems to function optimally.
PTSD is characterized by reduced function of the body's own GPCRs as a result of trauma and stress, leading to the symptoms of PTSD. Neuritek’s approach to treating PTSD is to activate the body’s own G-protein coupled receptor system to enable resilience to stress.
We anticipate that results of the proposed treatment development will have potential relevance and applicability in treating other psychiatric syndromes beside PTSD that are linked to high stress.